Drug Trial Radar · NCT03693989
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Last checked: Nov 20, 2026Latest source record: Dec 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Oct 4, 2018
Primary completion
Aug 7, 2019
Study completion Oct 22, 2019
Sponsor
- Lead sponsor
- Laboratorios Sophia S.A de C.V.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification. Hypothesis: The use of the ophthalmic emulsion PRO-145 is effective in decreasing the inflammatory response evaluated by means of cellularity in the anterior chamber, after phacoemulsification. Methodology: Phase III clinical trial, double-blind, controlled, parallel group, multicentre, randomized. Number of patients: 178 subjects divided into 2 groups (89 subjects per group), who will provide an eye for the evaluation of efficacy. Diagnosis and main inclusion criteria: Diagnosis: Postoperative phacoemulsification and foldable intraocular lens placement in a bag.
Conditions
- Cataract
Interventions
Difluprednate 0.05%Drug
Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
PrednefrinDrug
1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator. \- Route of administration: topical ophthalmic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Ability (VA)Time frame: day 28 at the final visit
- Adverse EventsTime frame: day 28 at the final visit
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Hospital de la luz
Mexico City, Mexico
Fundación de asistencia privada Conde de Valenciana
Mexico City, Mexico
Catarata y Glaucoma de Occidente
Guadalajara, Jalisco, Mexico
Novam y Vita
Guadalajara, Jalisco, Mexico
Vision Cirugia Ambulatoria
Monterrey, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.